GigaMune is developing in vivo gene delivery systems using virus-like particles to directly target T cell receptors and chimeric antigen receptors for the treatment of cancer and inherited blood disorders. This approach eliminates the manufacturing bottlenecks associated with ex vivo cell therapies, improving patient access and reducing associated medical risks.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current ex vivo cell therapies, like CAR-T, face manufacturing challenges that limit patient access and increase medical risks due to the complexity and cost of production. These bottlenecks hinder the widespread adoption of potentially life-saving treatments for cancer and inherited blood disorders.
Solution
GigaMune is developing in vivo cell therapies using virus-like particles (VLPs) for targeted gene delivery, directly modifying T cells and engineering chimeric antigen receptors (CARs) within the patient's body. This approach bypasses the complexities of ex vivo cell manipulation, reducing manufacturing costs and improving treatment accessibility. By delivering genes directly in vivo, GigaMune's technology aims to eliminate the need for lymphodepletion, a procedure associated with medical risks and infertility, further enhancing patient safety. The company leverages algorithms, high-throughput genomics, and artificial intelligence to discover viral envelopes, cell-tropic antibody fragments, and CARs with optimal targeting capabilities. GigaMune's pipeline includes in vivo cell therapies for multiple myeloma, acute myeloblastic leukemia (AML), and inherited blood disorders like sickle cell disease.
Target Audience
GigaMune's primary target audience includes patients with cancer and inherited blood disorders, as well as healthcare providers and researchers seeking more accessible and safer cell therapy options.
Features
- In vivo gene delivery using virus-like particles (VLPs) to directly target T cells and engineer CARs.
- Algorithms to search and analyze quadrillions of nucleotides for design of in vivo gene delivery particles.
- High-throughput genomics and artificial intelligence to identify CARs and cell-tropic antibodies.
- Targeted delivery eliminates the need for lymphodepletion.
- Pipeline of in vivo cell therapies for multiple myeloma, AML, and inherited blood disorders.